SEATTLE & BOSTON: #BioTech--Curi Bio, the industry leader in delivering human functional data to the drug discovery community, and Novoheart, maker of the industry’s most sophisticated and comprehensive human cardiac tissue engineering platforms, today announced the integration of Novoheart’s MyHeart™ human ventricular cardiac organoid chamber (hvCoC) platform, also known as the “Human Heart-in-a-Jar,” into Curi Bio’s proprietary cloud-based Pulse™ analysis platform. Through this collaboration and joint commercialization, this advancement enables users of Novoheart’s advanced hvCoC to analyze their data directly into Curi Bio’s Pulse analytics platform, providing biopharmaceutical researchers with deeper, actionable insights into cardiac drug development and disease modeling.

Novoheart’s MyHeart™ hvCoC is the only commercially available technology to date that enables the clinically informative assessment of human cardiac pump performance, which is not possible with other human engineered heart tissues on the market. Combined with complementary custom-designed hardware and software, the best-in-class “human heart-in-a-jar” allows drug screening and disease modeling with unprecedented biofidelity. With this advanced model, drug discoverers can provide insight into how new drugs affect cardiac pressure, stroke area, stroke work, and ejection fraction.

Curi Bio’s cloud-enabled Pulse platform combines state-of-the-art machine learning, high-throughput data processing, and intuitive visualization tools to streamline the functional analyses of complex biological datasets from human-relevant 3D and 2D models with a few simple mouse clicks. Curi Bio’s flagship Mantarray™ and Nautilai™ platforms currently utilize Pulse to provide scientists a seamless end-to-end workflow culminating in human relevant data. The integration of these industry-leading technologies expands the predictive power of Novoheart's hvCoC platform using turnkey software analytics. Cardiac scientists can now accelerate preclinical validation and reduce development costs with functional measurements of contractility.

“We are excited to collaborate with Curi Bio in integrating hvCoC data into Pulse,” said Dr. Kevin Costa, Co-founder and Chief Scientific Officer at Novoheart. “Our hvCoC–backed by years of development– represents the most complex in vitro model of human heart function available on the market. With this integration, we can offer our customers Curi Bio’s user friendly and powerful analytics pipeline. With these tools working together, researchers have the ability to rapidly extract deep analytics from their data, enhancing their ability to develop safer and more effective cardiac therapies.”

“This integration underscores Curi Bio’s ongoing commitment to delivering innovative solutions for human-relevant drug discovery,” said Dr. Nicholas A. Geisse, CEO at Curi Bio. “This partnership with Novoheart exemplifies how complementary collaborations can bring the next generation of human-specific cardiac technologies to the forefront of drug discovery, ultimately benefiting patients worldwide.”

About Curi Bio

Curi Bio unlocks novel workflows and delivers functional human data to inform biopharmaceutical R&D decision-making. Through an integrated platform featuring advanced 3D tissue models of disease, biosystems enabling clinically relevant functional analyses, and AI/ML-enabled insights, Curi Bio melds functional and analytical assessments for drug safety, efficacy, and potency. By offering leading global pharmaceutical end users an integrated preclinical platform along with highly predictive human stem cell tissue models to generate clinically-relevant data, Curi Bio is bridging the gap between preclinical R&D and clinical outcomes, accelerating the discovery and development of safer, more effective medicines.

For more information, please visit www.curibio.com.

About Novoheart

Novoheart is a global leader in next-generation human cardiac tissue models, revolutionizing drug discovery and therapeutic development. Its proprietary mini-Heart Platform, including the hvCoC “Human Heart-in-a-Jar,” offers clinically translatable insights for cardiac research, drug screening, and disease modeling. Novoheart’s mission is to advance human-specific alternatives to animal testing and accelerate the development of safer, more effective therapeutics.

For more information, please visit www.novoheart.com.

Fonte: Business Wire